to reproductive dysfunction. Dr. Ness published papers concerning the use of fetal fibronectin to predict ectopic and intrauterine pregnancies, endometriosis markers, and ovarian cancer biological markers. Since her formal training, she has lent her expertise to a number of organizations; she is current president of the American College of Epidemiology. She was a core member of the Early Markers of Adult Disease Workgroup and Study Assembly and codirector for the Symposium on Ovarian Cancer and High-Risk Women: Implications for Prevention, Screening, and Early Detection. She currently gives lectures concerning markers and molecular epidemiology.

Jennifer Van Eyk, Ph.D., is a professor of medicine in the Division of Cardiology and crossappointed to Biological Chemistry and Biomedical Engineering at Johns Hopkins University. She earned her doctoral degree from the University of Alberta. Her research combines physiology and proteomics to provide an in-depth analysis of the molecular basis for a variety of cardiac diseases ranging from myocardial ischemia to heart failure. In addition, her group develops serum/plasma biomarkers in which de novo discovery is coupled with validation. Dr. Van Eyk holds patents resulting from her biomarker research.

Dr. Van Eyk has been a Canadian Heart and Stroke Foundation Scholar (1996–2001) and Heart and Stroke Career Investigator (received in 2001), in addition to receiving a Canadian Institutes of Health Research Investigator Award prior to being recruited to Johns Hopkins. Dr. Van Eyk is a Fellow of the AHA, current chair of the Genomics and Translational Science Council for the AHA, a member of the senior editorial board of Proteomics: Clinical Application, and on the editorial board of the Journal of Physiology. She was a guest editor for a series on proteomics in a number of journals and has coedited two books in this area: Proteomic and Genomic Analysis of Cardiovascular Disease and Clinical Proteomics: From Diagnosis to Therapy.


John A. Wagner, M.D., Ph.D., is vice president of Clinical Pharmacology and Acting Modeling and Simulation Integrator in Strategically Integrated Modeling and Simulation at Merck & Co. Dr. Wagner is also an adjunct assistant professor in the Division of Clinical Pharmacology within the Department of Medicine at Jefferson Medical College at Thomas Jefferson University. He is a visiting clinical scientist within the Harvard–MIT Division of Health Sciences and Technology in the Center for Experimental Pharmacology and Therapeutics. He received his M.D. from Stanford University School of Medicine and his Ph.D. from Johns Hopkins University School of Medicine. His postgraduate training is in Internal Medicine and Molecular and Clinical Pharmacology. He is chair of the Pharma-



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement